CN103459377B - 作为钙敏感受体调变剂的苯并[b][1，4]噁嗪衍生物 - Google Patents

作为钙敏感受体调变剂的苯并[b][1，4]噁嗪衍生物 Download PDF

Info

Publication number
CN103459377B
CN103459377B CN201280013968.7A CN201280013968A CN103459377B CN 103459377 B CN103459377 B CN 103459377B CN 201280013968 A CN201280013968 A CN 201280013968A CN 103459377 B CN103459377 B CN 103459377B
Authority
CN
China
Prior art keywords
ethyl
methyl
benzo
oxazin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280013968.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103459377A (zh
Inventor
马洛耶库马尔·拉普拉塞德·舒克拉
沙德·甘加拉姆·安库斯
帕查普特·迪利普·维普尔
马克德·巴希尔·赛伊德
马哈德奥罗·巴斯卡·特雷安巴里克
舍康·桑贾伊·帕瓦尔
甘尼什·纳温钱德拉·格特
桑吉夫·阿南塔·库尔卡尼
文卡塔·P·帕列
拉金德·库马尔·坎博日
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Atlantis Holdings SA
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CN103459377A publication Critical patent/CN103459377A/zh
Application granted granted Critical
Publication of CN103459377B publication Critical patent/CN103459377B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201280013968.7A 2011-03-18 2012-03-16 作为钙敏感受体调变剂的苯并[b][1，4]噁嗪衍生物 Expired - Fee Related CN103459377B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN367/KOL/2011 2011-03-18
IN367KO2011 2011-03-18
PCT/IB2012/051268 WO2012127388A1 (en) 2011-03-18 2012-03-16 Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Publications (2)

Publication Number Publication Date
CN103459377A CN103459377A (zh) 2013-12-18
CN103459377B true CN103459377B (zh) 2016-09-07

Family

ID=54192843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280013968.7A Expired - Fee Related CN103459377B (zh) 2011-03-18 2012-03-16 作为钙敏感受体调变剂的苯并[b][1，4]噁嗪衍生物

Country Status (16)

Country Link
US (1) US9464063B2 (enExample)
EP (1) EP2686306B1 (enExample)
JP (1) JP6033835B2 (enExample)
KR (1) KR20140051846A (enExample)
CN (1) CN103459377B (enExample)
AP (1) AP2013007153A0 (enExample)
AU (1) AU2012232706B2 (enExample)
BR (1) BR112013023914A2 (enExample)
CA (1) CA2829466A1 (enExample)
EA (1) EA024893B9 (enExample)
IL (1) IL228461A0 (enExample)
MX (1) MX2013010670A (enExample)
PH (1) PH12013501899A1 (enExample)
SG (1) SG193331A1 (enExample)
WO (2) WO2012127388A1 (enExample)
ZA (1) ZA201306837B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24325B1 (es) 2012-02-24 2018-03-13 Lupin Atlantis Holdings Sa Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores
WO2013136288A1 (en) 2012-03-16 2013-09-19 Lupin Limited Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
WO2014033604A1 (en) 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
CA2920818A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
MX367723B (es) 2013-10-25 2019-09-03 Novartis Ag Compuestos de anillos fusionados bicíclicos derivados de piridilo como inhibidores de fgfr4.
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
EP3200786B1 (en) 2014-10-03 2019-08-28 Novartis AG Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN104464530B (zh) * 2014-11-18 2017-08-25 深圳市华星光电技术有限公司 曲面型显示装置
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
ES2899906T3 (es) 2015-07-06 2022-03-15 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
ES2875562T3 (es) 2017-01-11 2021-11-10 Alkermes Inc Inhibidores bicíclicos de histona desacetilasa
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
BR112022012663A2 (pt) 2019-12-27 2022-09-06 Lupin Ltd Composição farmacêutica de moduladores de casr e métodos e usos da mesma
FI4090654T3 (fi) 2020-01-17 2025-09-30 Lupin Ltd Menetelmiä, prosesseja ja välituotteita kromaaniyhdisteiden valmistamiseksi

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090069A1 (fr) * 2000-05-24 2001-11-29 Centre National De La Recherche Scientifique (Cnrs) Composes possedant une activite calcimimetique
CN101175724A (zh) * 2005-05-19 2008-05-07 安斯泰来制药有限公司 吡咯烷衍生物或其盐
US20100029687A1 (en) * 2006-11-16 2010-02-04 Astellas Pharma Inc. Piperidine derivative or salt thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1109880A (zh) 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
EP2392328A1 (en) * 2005-05-09 2011-12-07 Hydra Biosciences, Inc. Compounds for modulating TRPV3 Function
WO2008041118A2 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008057282A1 (en) * 2006-10-26 2008-05-15 Amgen Inc. Calcium receptor modulating agents
CA2706076A1 (en) 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
CN103980309B (zh) 2008-10-03 2016-04-06 味之素株式会社 CaSR激动剂
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010090069A1 (ja) * 2009-02-05 2010-08-12 ヤンマー株式会社 Ｅｇｒ装置及びこれを備えたエンジン装置
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090069A1 (fr) * 2000-05-24 2001-11-29 Centre National De La Recherche Scientifique (Cnrs) Composes possedant une activite calcimimetique
CN101175724A (zh) * 2005-05-19 2008-05-07 安斯泰来制药有限公司 吡咯烷衍生物或其盐
US20100029687A1 (en) * 2006-11-16 2010-02-04 Astellas Pharma Inc. Piperidine derivative or salt thereof

Also Published As

Publication number Publication date
EP2686306B1 (en) 2017-01-04
JP2014510097A (ja) 2014-04-24
US9464063B2 (en) 2016-10-11
AP2013007153A0 (en) 2013-09-30
SG193331A1 (en) 2013-10-30
CA2829466A1 (en) 2012-09-27
ZA201306837B (en) 2015-05-27
JP6033835B2 (ja) 2016-11-30
EP2686306A1 (en) 2014-01-22
AU2012232706A1 (en) 2013-09-26
WO2012127385A1 (en) 2012-09-27
EA201370205A1 (ru) 2014-01-30
PH12013501899A1 (en) 2013-11-25
WO2012127388A1 (en) 2012-09-27
CN103459377A (zh) 2013-12-18
US20140018358A1 (en) 2014-01-16
NZ616676A (en) 2015-09-25
EA024893B9 (ru) 2017-01-30
AU2012232706B2 (en) 2016-12-15
EA024893B1 (ru) 2016-10-31
IL228461A0 (en) 2013-12-31
MX2013010670A (es) 2013-12-06
BR112013023914A2 (pt) 2016-12-13
KR20140051846A (ko) 2014-05-02

Similar Documents

Publication Publication Date Title
CN103459377B (zh) 作为钙敏感受体调变剂的苯并[b][1，4]噁嗪衍生物
US20230286961A1 (en) Substituted tetrahydrofurans as modulators of sodium channels
KR102482673B1 (ko) 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
EP2683697B1 (en) Substituted morpholines as modulators for the calcium sensing receptor
CN104350047B (zh) 作为钙敏感受体调节剂的取代苯并二氢吡喃化合物
WO2015162538A1 (en) Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2013136288A1 (en) Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
WO2014033604A1 (en) Arylalkylamine compounds as calcium sensing receptor modulators
HK1192544B (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
HK1192544A (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
US9493396B2 (en) Substituted naphthalene compounds as calcium sensing receptor modulators
WO2024192247A2 (en) Sigma-1 receptor antagonists and their applications
NZ616676B2 (en) Benzo [b] [1,4] oxazin derivatives as calcium sensing receptor modulators
WO2025177150A1 (en) Compound as parp1 inhibitor and pharmaceutical composition comprising the same
OA16592A (en) Benzo [B][1,4] oxazin derivatives as calcium sensing receptor modulators.
OA21241A (en) Substituted tetrahydrofurans as modulators of sodium channels.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1192544

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160826

Address after: Swiss Chu Gezhou

Patentee after: Atlantis Atlantis Holdings Ltd

Address before: Maharashtra

Patentee before: Lupin Limited

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1192544

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160907

Termination date: 20180316